- The Honorable Larry Bucshon, MD
US House of Representatives
2313 Rayburn House Office Building
Washington, DC 20515 - The Honorable Diana DeGette
US House of Representatives
2111 Rayburn House Office Building
Washington, DC 20515
Submitted electronically via cures.rfi@mail.house.gov
SUBJECT: Comments on Request for Feedback on Cures 2.0 Legislation
Dear Rep. DeGette and Dr. Buschon:
On behalf of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), we appreciate the opportunity to provide comments on the progress of and future directions for the CURES 2.0 Act. The 21st Century Cures Act has successfully advanced multiple initiatives, but there are more remains to be done.
Support for the Use of Registry Data
Although the 21st Century Cures Act included a provision for the creation of a real-world evidence (RWE) task force within the Department of Health and Human Services (HHS), little progress has been made over the last several years in this regard. We continue to believe that real-world data sources, such as properly designed prospective data registries, are cost-effective alternatives to costly and time consuming randomized controlled trials. In addition to the use of registry data to speed innovation and device approval, registry expertise is useful for post-market surveillance.
Click here to view the full Neurosurgery Provides Recommendations for Cures 2.0 Legislation
